Related Experiment Video

Updated: Aug 31, 2025

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.4K

Applications of cardiac biomarkers in chronic kidney disease

Alexander Kula1, Nisha Bansal2

  • 1Division of Pediatric Nephrology, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.

Current Opinion in Nephrology and Hypertension
|August 25, 2022
PubMed

Insights

N-terminal pro-B-type natriuretic peptide (Nt-proBNP) and troponin show promise as effective biomarkers for cardiovascular disease risk in chronic kidney disease (CKD) patients. Further research is needed to establish CKD-specific cutoffs and guide therapy.

Area of Science:

  • Biomarkers
  • Cardiovascular Disease
  • Nephrology

Background:

  • Cardiovascular disease (CVD) is the primary cause of mortality in chronic kidney disease (CKD) patients.
  • Complex mechanisms link CKD and CVD, necessitating improved understanding through serum biomarkers.
  • N-terminal pro-B-type natriuretic peptide (Nt-proBNP) and troponin are established biomarkers in non-CKD populations.

Purpose of the Study:

  • To review the efficacy and clinical application of Nt-proBNP and troponin in individuals with CKD.
  • To summarize current evidence on the utility of these biomarkers in the CKD population.

Main Methods:

  • Review of existing literature on Nt-proBNP and troponin in CKD.
  • Analysis of studies investigating biomarker interpretation and clinical application in CKD patients.

Main Results:

  • Elevated Nt-proBNP and troponin levels in CKD predominantly indicate cardiovascular disease, despite partial renal clearance.
  • Both biomarkers are associated with increased risk of future cardiovascular events in CKD.
  • Research is ongoing to determine CKD-specific cutoffs and therapeutic guidance using these biomarkers.

Conclusions:

  • Nt-proBNP and troponin are highly suitable biomarkers for CKD due to assay availability and accuracy.
  • These biomarkers warrant focused research for cardiovascular risk reduction in CKD.
  • They can aid in identifying high-risk patients, suggesting mechanisms, and assessing treatment efficacy.
Abstract

More Related Videos

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

796
A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

20.9K

Related Concept Videos

Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
60
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
73
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
70
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
290
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
47
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
195